IASO Bio Announces Strategic Collaborations to Accelerate Global Commercialization of CAR-T Therapy Fucaso®

Nanjing, Shanghai, and San Jose, CaliforniaNovember 10, 2023PR Newswire -- November 5, 2023, the 6th China International Import Expo was held in Shanghai. IASO Bio showcased several of its cutting-edge cell therapy technologies and innovative products at the expo. Meanwhile, it also reached agreements with multiple top pharmaceutical institutions regarding its world-first fully human CAR-T product, Fokso.^®The diversified strategic cooperation is jointly committed to promoting the development of the cell therapy field. By sharing resources and technology, IASO Bio and its partners will work together to create innovative service solutions, making cell therapy drugs benefit more patients.

Explore Innovative Patient Service Solutions, Unite Multilateral Efforts

IASO Bio is committed to serving patients worldwide, and this signing collaborationSinopharm Group Co.,Ltd., Shanghai Pharmaceutical Co.,Ltd. and CR PHARMA COMMJointly Promoted by Multiple Parties: Fokasol^®The commercialization process, expanding market channels, and improving the accessibility of medicines. Through the deepening cooperation with leading enterprises in China's pharmaceutical industry, it will benefit Fokasol.^®The commercialization process provides strong support and guarantees, benefiting more patients. Meanwhile, IASO Bio continues to focus on the accessibility and affordability of innovative drugs for patients, in collaboration withMediTrust Health, Medi CoverFurther deepened their cooperation in patient care and service. As an industry-leading innovative medical service and security platform, they will collaborate with IASO Bio to explore diversified payment methods and cooperation models, further constructing a multi-layered payment system for patients with hematological tumors, providing more flexible and sustainable medical security.

Mr. Zhang Hua, Senior Vice President and Chief Commercial Officer of IASO Bio, stated"IASO Bio has gradually grown from a start-up to an innovation leader in the biopharmaceutical field, thanks to the strong support of every partner. IASO Bio is building a medical center in China that serves the world, showcasing China's innovative technology and medical capabilities. We hope that through strategic cooperation with many outstanding pharmaceutical companies, we can help multiple myeloma patients in China and even globally benefit from targeted BCMA CAR-T therapy. Meanwhile, customized healthcare and services will become a new direction for the future development of the pharmaceutical industry."

IASO Bio Will Fully Seize Every Opportunity and Pragmatically Advance Various Strategic Collaborations. In the Future, IASO Bio Will Continue to Focus on the Research and Development of Innovative Cell Therapies and Technologies, Working Hand in Hand with Partners to Bring More Effective and Safer Treatment Solutions to Patients Worldwide.